| __timestamp | Catalent, Inc. | Dr. Reddy's Laboratories Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 1229100000 | 56369000000 |
| Thursday, January 1, 2015 | 1215500000 | 62786000000 |
| Friday, January 1, 2016 | 1260500000 | 62427000000 |
| Sunday, January 1, 2017 | 1420800000 | 62453000000 |
| Monday, January 1, 2018 | 1710800000 | 65724000000 |
| Tuesday, January 1, 2019 | 1712900000 | 70421000000 |
| Wednesday, January 1, 2020 | 2111000000 | 80591000000 |
| Friday, January 1, 2021 | 2646000000 | 86645000000 |
| Saturday, January 1, 2022 | 3188000000 | 100551000000 |
| Sunday, January 1, 2023 | 3216000000 | 42907000000 |
| Monday, January 1, 2024 | 3428000000 | 115557000000 |
Unlocking the unknown
In the ever-evolving pharmaceutical industry, understanding cost structures is crucial. This analysis delves into the cost of revenue trends for Dr. Reddy's Laboratories Limited and Catalent, Inc. from 2014 to 2024. Over this decade, Dr. Reddy's Laboratories consistently reported higher costs, peaking at approximately 115.6 billion in 2024, a staggering 105% increase from 2014. In contrast, Catalent, Inc. showed a more modest growth, with costs rising by about 179% to 3.4 billion in 2024. Notably, 2023 saw a dip for Dr. Reddy's, with costs dropping to 42.9 billion, highlighting potential strategic shifts or market challenges. This comparative analysis underscores the dynamic nature of cost management in the pharmaceutical sector, offering valuable insights for investors and industry stakeholders.
Cost Insights: Breaking Down Merck & Co., Inc. and Catalent, Inc.'s Expenses
Analyzing Cost of Revenue: Pfizer Inc. and Catalent, Inc.
Cost Insights: Breaking Down Neurocrine Biosciences, Inc. and Dr. Reddy's Laboratories Limited's Expenses
Cost of Revenue: Key Insights for Dr. Reddy's Laboratories Limited and BioMarin Pharmaceutical Inc.
Cost of Revenue Trends: Dr. Reddy's Laboratories Limited vs Sarepta Therapeutics, Inc.
Cost of Revenue Comparison: Dr. Reddy's Laboratories Limited vs Lantheus Holdings, Inc.
Comparing Cost of Revenue Efficiency: Dr. Reddy's Laboratories Limited vs Grifols, S.A.
Dr. Reddy's Laboratories Limited vs CRISPR Therapeutics AG: Efficiency in Cost of Revenue Explored
Dr. Reddy's Laboratories Limited vs Ligand Pharmaceuticals Incorporated: Efficiency in Cost of Revenue Explored
Dr. Reddy's Laboratories Limited vs Geron Corporation: Efficiency in Cost of Revenue Explored
Catalent, Inc. vs MorphoSys AG: Efficiency in Cost of Revenue Explored
Catalent, Inc. vs Ligand Pharmaceuticals Incorporated: Efficiency in Cost of Revenue Explored